HEMATOPOIETIC PROGENITOR CELLS

乳腺癌是最常见的女性癌症。 其发病率 在年轻女性中迅速增加，早期发现不常见， 肿瘤往往更具侵略性，生产年的损失， 最棒的 自体造血祖细胞大剂量化疗 细胞支持（AHPCS）已被证明对预后不良的 乳腺癌患者。本ROI的重点是评估AHPCS 使用CD34+造血祖细胞，然后使其经受 更多操作（S）该项目的目标是： L.最大限度地减少自体移植物中乳腺癌的数量。 2.在乳腺癌中产生快速和持久的骨髓重建 接受HDC治疗的患者。 3.为了降低输注大量未纯化AHPCS的毒性， 使用纯化的祖细胞。 4.开发造血祖细胞的体外扩增作为一种新的 技术，并证明其临床实用性。

Breast cancer is the most common female cancer. Its incidence is increasing rapidly in younger women, where early detection is infrequent, tumors tend to be more aggressive, and loss of productive years is greatest. High-dose chemotherapy with autologous hematopoietic progenitor cell support (AHPCS) has demonstrated effectiveness for poor-prognosis breast cancer patients. The focus of this ROl is the evaluation of AHPCS using CD34+ hematopoietic progenitor cells, which are then subjected to further manipulation(s). The goals of this project are to: l. Maximally decrease the amount of breast cancer in the autograft. 2. To produce rapid and durable marrow reconstitution in breast cancer patients receiving HDC. 3. To reduce the toxicity of infusing large volumes of unpurified AHPCS by using purified progenitor cells. 4. To develop ex vivo expansion of hematopoietic progenitors as a novel technology, and demonstrate its clinical utility.